Focus: Trevi Therapeutics is a public biotech company focused on small-molecule therapeutics for respiratory, dermatology, and neurology indications. The company operates as a clinical-stage enterprise with a lean pipeline centered on nalbuphine ER formulations.
Profile data last refreshed 37m ago · AI intelligence enriched 2mo ago
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Suitable for early-career clinicians or operational specialists seeking exposure to clinical-stage drug development with meaningful trial influence, but carries significant financial and execution risk typical of pre-revenue biotechs.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Trevi Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Trevi Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Trevi Therapeutics (TRVI) director receives 35,000-share stock option grant - Stock Titan
Trevi Therapeutics (TRVI) director receives 35,000-share stock option grant Stock Titan
Trevi Therapeutics (TRVI) doubles authorized stock, adds 8,000,000-plan shares - Stock Titan
Trevi Therapeutics (TRVI) doubles authorized stock, adds 8,000,000-plan shares Stock Titan
[Form 4] Trevi Therapeutics, Inc. Insider Trading Activity - Stock Titan
[Form 4] Trevi Therapeutics, Inc. Insider Trading Activity Stock Titan
Trevi Therapeutics (TRVI) director receives 35K nonstatutory option grant - Stock Titan
Trevi Therapeutics (TRVI) director receives 35K nonstatutory option grant Stock Titan
Director at Trevi Therapeutics (NASDAQ: TRVI) awarded 35,000 stock options - Stock Titan
Director at Trevi Therapeutics (NASDAQ: TRVI) awarded 35,000 stock options Stock Titan
Director at Trevi Therapeutics (TRVI) receives 35,000 stock options award - Stock Titan
Director at Trevi Therapeutics (TRVI) receives 35,000 stock options award Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo